Neuraxis (NRXS) Stock
Small cap healthcare company developing neurology products. Here's the price, business snapshot, and what's worth knowing about Neuraxis in October 2026.
Neuraxis Inc (NRXS) is a small‑cap healthcare company with a market capitalisation near $36.5 million. Investors should know it operates in the medical/neurology space, where product development, regulatory approvals and specialist adoption can determine commercial success. Small companies like Neuraxis may offer exposure to niche innovation but also carry elevated operational and financing risks. Key considerations include the company’s cash runway, recent regulatory or clinical milestones, partnerships or licensing deals, and how management plans to scale revenue. Liquidity for the shares can be limited, which may amplify price moves. This summary is educational and not personal advice: values can rise and fall and returns are not guaranteed. Before investing, check the latest filings, analyst notes and regulatory announcements, and consider whether the stock fits your risk tolerance and time horizon.
Neuraxis (NRXS) Stock Forecast
Analyst price target, next 12 months
$11.00
+54.7% vs today's $7.11
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Neuraxis have a consensus 12-month target of $11.00, above the current price of $7.11.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 26 May 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying NEURAXIS INC stock with a target price of $11, indicating potential growth.
Financial Health
Neuraxis Inc is generating solid revenue and cash flow with a strong profit margin.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Small‑cap dynamics
A modest market cap can mean higher growth potential but also greater volatility and limited liquidity; suitability depends on your risk tolerance.
Innovation and regulation
If the company develops medical technologies, innovation and regulatory approvals are central value drivers — clinical outcomes and approvals can change prospects quickly.
Research checklist
Look for clinical data, cash runway, partnerships and recent filings; remember past performance doesn’t guarantee future returns.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
